Elucidating the Role of Inherited Complement System Defects in the Molecular Pathophysiology of Sepsis and Purpura Fulminans
Elucidating the Role of Inherited Complement System Defects in the Molecular Pathophysiology of Sepsis and Purpura Fulminans
批准号:
10246412
负责人:
Pavan Bendapudi
金额:
$13.13万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2023-07-31
关键词:
AddressAgeAnti-Inflammatory AgentsAnticoagulationBacterial InfectionsBiologicalBiological MarkersBlood Coagulation DisordersCellsCessation of lifeClinicalCoagulation ProcessCodeComplementComplement component C1ComplicationDataData SetDefectDevelopmentDiseaseDisseminated Intravascular CoagulationEthnic OriginFactor XaFailureFoundationsFunctional disorderGenerationsGeneticGenetic Predisposition to DiseaseGoalsHumanIndividualInfectionInflammationInflammatoryInheritedIntegrinsInterventionLeadLinkMacrophage-1 AntigenMolecularMolecular ProfilingMutationNational Heart, Lung, and Blood InstituteNatural ImmunityNeisseria meningitidisOrganPathway interactionsPatientsPatternPlasmaPlayPopulationProductionProteinsPublic HealthPurpura FulminansResearchRoleSepsisSignal PathwaySignal TransductionSpecimenStreptococcus pneumoniaeTherapeutic InterventionThromboplastinThrombosisU937 CellsUp-RegulationVariantWorkbiobankclinical predictorscohortcomorbiditycomorbidity Indexcomplement pathwaycomplement systemcytokinedisease phenotypeexome sequencingfollow-upgain of functiongene discoveryimmunoregulationinsightloss of functionmacrophagemonocytemortalitymutantmutational statusnovelpathogen exposurepathogenic microbereceptorrepositoryresponsesepticseptic patientssexsystemic inflammatory responsethromboinflammationthrombotictrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Purpura fulminans (PF) is a rare but devastating complication of sepsis in which patients
develop a highly thrombotic subtype of disseminated intravascular coagulation (DIC), leading to
dismemberment, end organ damage, and death. PF can be triggered by a range of bacterial
infections and is distinguished by extremely high levels of circulating cytokines and failure of key
anti-inflammatory pathways which cause a marked upregulation of procoagulant tissue factor
(TF) expression by activated monocytes. Because PF represents an extreme disease phenotype,
leveraging our findings in this disorder could yield key insights into the broader problem of septic
DIC. However, at present almost nothing is known about the molecular pathophysiology and
genetic predisposition underlying PF. Utilizing germline whole exome sequencing (WES) and a
targeted gene discovery approach, we have found a significant enrichment in rare, deleterious
coding variants in the complement systems of patients with PF compared to unselected patients
with sepsis (P<0.0001). Intriguingly, we also found that these variants may be associated with
increased mortality in unselected sepsis patients despite the absence of overt PF. We
hypothesize that complement system defects lead to heightened systemic inflammation and
procoagulant activity, resulting in the development of coagulopathy. In Aim 1 of this project, we
will follow up on our preliminary results by performing WES on clinically well-annotated
specimens in the NHLBI BioLINCC repository from septic patients without overt PF. We will
correlate complement mutational status to plasma biomarkers of thrombosis and inflammation
after adjusting for age, sex, ethnicity, and comorbidities in order to understand if complement
system defects are associated with worsened thrombo-inflammation in sepsis. In Aim 2, we will
functionally characterize a novel class of rare PF-associated variants in complement receptors 3
and 4 (CR3/4) with respect to their impact on monocyte-driven inflammation and thrombosis.
The proposed work will provide important new insights into the relationship between innate
immunity and dysregulated coagulation and generate a foundational WES dataset with
biological correlates for studying the widespread problem of coagulopathy in sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Coagulation Factor XII Recruitment and Activation During Thrombus Formation
-
批准号:10741964
-
项目类别:
-
资助金额:$72.17万
-
财政年份:2023
-
负责人:Pavan Bendapudi
-
依托单位:
Mechanisms of Coagulation Factor XII Recruitment and Activation at the Platelet Surface
-
批准号:10424806
-
项目类别:
-
资助金额:$8.65万
-
财政年份:2022
-
负责人:Pavan Bendapudi
-
依托单位:
Mechanisms of Coagulation Factor XII Recruitment and Activation at the Platelet Surface
-
批准号:10588194
-
项目类别:
-
资助金额:$8.65万
-
财政年份:2022
-
负责人:Pavan Bendapudi
-
依托单位:
Elucidating the Role of Inherited Complement System Defects in the Molecular Pathophysiology of Sepsis and Purpura Fulminans
-
批准号:10044028
-
项目类别:
-
资助金额:$13.13万
-
财政年份:2020
-
负责人:Pavan Bendapudi
-
依托单位:
The Role of Coagulation Factor XII in Hemostasis and Thrombosis
-
批准号:10194578
-
项目类别:
-
资助金额:$16.34万
-
财政年份:2017
-
负责人:Pavan Bendapudi
-
依托单位:
The Role of Coagulation Factor XII in Hemostasis and Thrombosis
-
批准号:9294310
-
项目类别:
-
资助金额:$16.34万
-
财政年份:2017
-
负责人:Pavan Bendapudi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: